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Abstract 
 
Glucocorticoids (GC) are commonly used for immunomodulation and steroid 
replacement.  Long-term use can, however, result in side effects including growth 
retardation in children due to their actions on growth plate chondrocytes.  Recently, a 
non-steroidal anti-inflammatory agent (AL-438) that acts through the glucocorticoid 
receptor (GR) has been described. Studies with AL-438 have shown it retains full 
anti-inflammatory efficacy but has reduced negative effects on osteoblasts compared 
to those elicited by prednisolone (Pred) or dexamethasone (Dex).  We have used the 
murine chondrogenic ATDC5 cell line to compare the effects of AL-438 with those of 
Dex and Pred on chondrocyte dynamics.  During chondrogenesis, Dex and Pred (10-
6M) exposure resulted in a reduction in cell proliferation (30.3% and 18.8% 
respectively (p<0.05)) and proteoglycan synthesis (56% and 53.9% respectively 
(p<0.05)), whereas exposure to AL-438 (10-6M) had no effect.  LPS-induced IL-6 
production in ATDC5 cells was significantly reduced by Dex or AL-438 (10-6M) 
(58.1% and 55.4% respectively; p<0.05) showing that AL-438 has similar anti-
inflammatory efficacy to Dex in these cells.  Fetal mouse metatarsals grown in the 
presence of Dex were significantly shorter than control bones (18.5% shorter at day 
10 (p<0.05) and 22.2% shorter at day 12 (p<0.01)) whereas AL-438 treated 
metatarsals paralleled control bone growth.  These results indicate that the adverse 
effects Dex or Pred have on chondrocyte proliferation and bone growth were 
attenuated following AL-438 exposure, suggesting that AL-438 has a reduced side 
effect profile on chondrocytes compared to other GCs.  This could prove important in 
the search for new anti-inflammatory treatments for children. 
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Introduction 
 
Glucocorticoids (GC) are commonly used as anti-inflammatory or 
immunosuppressive treatments, and it has been estimated that 5-10% of children may 
require some form of GC therapy at some time in childhood [1].  Since the 
introduction of GCs in the treatment of rheumatoid arthritis in 1949, the therapeutic 
applications of these drugs have greatly broadened to encompass a large number of 
non-endocrine and endocrine diseases [2].  Despite intense efforts to maximise the 
beneficial effects and to minimise the side effects of GCs, adverse effects of GC 
medication are still common.  Impairment of childhood growth with long-term GC 
was described nearly 50 years ago, however recent studies have shown that growth 
retardation can also occur with short-term GC therapy.  In addition, it has been shown 
that the severity of side-effects may vary depending on the type of GC used [3,4].   
 
Normal cartilage formation and bone growth is dependent upon chondrocyte 
progression through the growth plate as demonstrated by a number of null mutations 
that have been introduced in mice.  Growth plate chondrocytes regulate the rate of 
longitudinal bone growth through the precise regulation of chondrocyte proliferation, 
hypertrophy and apoptosis [5, 6]. The mechanisms by which GC induce failure in the 
growth process are presently unclear but GCs act locally to inhibit longitudinal bone 
growth, suggesting a mechanism intrinsic to the growth plate.  Baron and colleagues 
[7] reported that local infusion of GC into the growth plate decreased the ipsilateral 
tibial growth rate with no effects on the contralateral limb.  In addition, both 
Silvestrini et al [8] and Smink et al [9] reported that GC reduced growth cartilage 
width, probably by inhibiting chondrocyte proliferation and increasing the apoptosis 
of terminal hypertrophic chondrocytes.   Studies by ourselves [4,10] and others are in 
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agreement; reporting that GC impair chondrocyte proliferation and increase apoptosis 
[11, 12, 13, 14, 15].  The cellular machinery by which GC exerts control over 
chondrocyte dynamics is presently unclear but has been postulated to involve 
disruption to the growth hormone (GH) - insulin-like growth factor (IGF) axis.  GH & 
IGF-I play essential roles in growth and development [16] with IGFs being mainly 
bound to IGF binding proteins (IGFBP) 1, 2 & 3 that reduce IGF bioavailability. 
There is some conflicting evidence that GC effects on growth may be mediated via 
changes in GH sensitivity as well as changes in IGFBP expression [17] and IGF-I 
dependent phosphorylation events [18, 19, 20] 
 
Recently, a non-steroidal inflammatory agent (AL-438) that acts through the 
glucocorticoid receptor (GR) has been described [21].  Studies with AL-438 using the 
carrageenan-induced paw edema assay and the adjuvant arthritis models in rats have 
shown it retains full anti-inflammatory efficacy but has reduced negative effects on 
bone compared to those elicited by Prednisolone (Pred) [21].  It is presently unknown 
whether AL-438 has less detrimental effects on growth plate chondrocytes than other 
commonly used anti-inflammatory steroids.  In this context, the effects of AL-438 
have been compared with those of Dexamethasone (Dex) and Pred using the  
chondrogenic ATDC5 cell line and the fetal mouse metatarsal organ culture model. 
The ATDC5 cell line established by Atsumi et al. [22] from the mouse 
teratocarcinoma cells AT805, mimics many of the events described for differentiation 
of epiphyseal chondrocytes This line has less phenotypic diversity than cell cultures of 
primary chondrocytes, and also allows the study of the differentiation of 
mesenchymal cells into chondrocytes and the terminal differentiation of proliferating 
to hypertrophic chondrocytes [4].  The fetal mouse metatarsal explant culture provides 
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a more physiological model for studying bone growth.  It maintains cell-cell and cell-
matrix interactions and the direct assessment of bone growth and histological 
architecture can be determined [23, 24].   
 
Materials and Methods 
 
 
Chondrocyte cell culture 
The ATDC5 chondrocyte cell line was obtained from the RIKEN cell bank (Ibaraki, 
Japan), and cells were cultured at a density of 6000 cells per cm2 in differentiation 
medium in multi-well plates [25] (Costar, High Wycombe, UK).  Differentiation 
medium contained DMEM/Ham’s F12 (Invitrogen, Paisley, UK), 5% FCS 
(Invitrogen), 3x10-8M sodium selenite and 10µg/ml human transferrin (Sigma, Poole, 
UK) and insulin (10µg/ml; Sigma).  Cells were incubated at 37oC in a humidified 
atmosphere containing 5% CO2/95% air for up to 17 days and the medium was 
changed every second day after reaching confluency (day 6).  
 
Gene expression 
In order to study and compare the effects of AL-438 (Ligand Pharmaceuticals, San 
Diego, USA), Dex and Pred (Sigma) during both chondrogenesis (days 6-10) and 
terminal differentiation phases (days 13-17), all three compounds were added to the 
cells at the beginning of both time points (days 6 and 13, respectively) at a final 
concentration of 10-6M [4] in 0.01% dimethyl sulfoxide (DMSO).  Control cultures 
contained 0.01% DMSO only. Cells were grown in the presence of the compounds for 
4 days, at which point RNA was extracted, reverse transcribed and analysed for 
aggrecan gene expression by semiquantitative (sq) and quantitative (q) RT-PCR. 
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RNA extraction 
Total RNA was extracted from chondrocytes by repeated aspiration though a 25-
gauge syringe needle in 1ml Ultraspec (Biotecx, Houston, Texas, USA).  After 
extraction with chloroform, RNA in the aqueous phase was purified with isopropanol 
and bound to 50µl RNA Tack resin, before washing with 75% ethanol.  The RNA was 
then eluted in 100µl nuclease free water and treated with DNase.  For each sample the 
260/280 ratio was determined, and the samples diluted to a concentration of 60ng/µl 
and stored at -80oC.   
 
 Semiquantative and Quantitative RT-PCR 
Gene expression was analysed by both sq [26] and qPCR.  RNA samples or blanks 
(containing nuclease-free water in place of RNA) were reverse transcribed in 20µl 
reactions with 200ng random hexamers and 200U Superscript II reverse transcriptase 
using the Superscript preamplification protocol (Invitrogen).  sqPCR was performed 
in 20µl reactions containing cDNA equivalent to 10ng RNA and 200nM gene-specific 
primers (Aggrecan: forward 5’ CGAGAATGACACCTGCTAGG 3’, reverse 3’ 
AAGAAGACAGGACCAGGAAGG 5’; 18S:  Unknown, purchased from Ambion)       
in 10XPCR buffer [26].  The cycling profile was 1 min at 92oC (first cycle 2 min), 1 
min at 55oC and 1 min at 72oC.  The number of cycles varied between genes to ensure 
that the reactions were in the exponential phase.  Reaction products were analysed on 
1.5% agarose gels in the presence of ethidium bromide (250µg/l) and a digital image 
of each gel was captured using a gel documentation system.  qPCR was performed 
using the Stratagene Mx3000P real-time QPCR system (Stratagene,  California, 
USA).  Primers for Aggrecan were obtained from SuperArray Bioscience (Maryland, 
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USA; sequence unknown) and primers for GAPDH were designed using the software 
programme Primer3 (Whitehead Institute for Biomedical Research) (forward 5’ 
TGAGGCCGGTGCTGAGTATGTCG 3’, reverse 5’ 
CCACAGTCTTCTGGGTGGCAGTG 3’).  cDNA (5ng) was amplified in triplicate 
using the Platinum SYBR Green qPCR SuperMix (Invitrogen, Paisley, UK) under the 
following conditions:  cDNA was denatured for 2 minutes at 95 oC, followed by 40 
cycles consisting of 15 s at 95oC and 30 s at 60oC and 1 cycle consisting of 1 min at 
95oC and 30 s at 60 oC.  Each reaction contained 10µl cDNA, 25µl Platinum SYBR 
Green qPCR Super-Mix, 1µl ROX Reference Dye, and 250nM primer  in a total 
volume of 40µl.  Fold changes, normalised for the expression of GAPDH, were 
calculated using the comparative method [27]. 
 
Rate of chondrocyte proliferation 
Compounds (10-6M, 10-7M or 10-8M) were added to the cells during both time points 
as previously described, and were incubated for 24h.  Chondrocyte proliferation was 
assessed by incubating the chondrocytes with 0.2µCi/ml [3H]thymidine (37MBq/ml; 
Amersham Pharmacia Biotech, Bucks, UK) for the last 2h of the incubation period 
and the amount of radioactivity incorporated into trichloroacetic acid insoluble 
precipitates was measured.  The effect of AL-438 on chondrocyte number was also 
determined by incubating the cells with AL-438, Pred, or Dex for 48h and counting 
the cells directly in a haemocytometer chamber. 
 
Alkaline Phosphatase activity and Proteoglycan production 
Dex, Pred and AL-438 (10-6M) or 0.01% DMSO were added to ATDC5 cells at day 6 
or day 13 for 96h.  For analysis of alkaline phosphatase (ALP) activity, cells were 
rinsed with phosphate buffered saline (PBS) and lysed with 0.9% NaCl and 0.2% 
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Triton X-100 and centrifuged at 12000g for 15min at 4oC.  The supernatant was 
assayed for protein content and ALP activity as a measure of cell number and 
chondrocyte differentiation respectively.  The protein content of the supernatant was 
measured using the Bio-Rad protein assay reagent (Bio-Rad Laboratories; Hemel 
Hempstead; UK) and gamma globulin was used as a standard.  For analysis of 
proteoglycan production, ATDC5 cells were washed twice with PBS, fixed in 95% 
methanol for 20min and stained with 1% Alcian Blue 8GX in 0.1M HCl overnight 
and rinsed with distilled water.  Alcian Blue stained cultures were extracted with 1ml 
6M Guanidine-HCl for 6h at room temperature and the optical density (O.D) was 
measured at 630nm using a Jenway 6105 spectrophotometer [28]. 
 
Apoptosis 
Apoptosis was measured using the Caspase-3 Apoptosis assay, which was used 
according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN, 
USA).  Dex, Pred and AL-438 (10-6M) were added to the cells during chondrogenesis 
or terminal differentiation periods for 24h.  As a positive control, cells were incubated 
as above with 10ng/ml TNFα (Autogen Bioclear, Wiltshire, UK). 
 
Determination of anti-inflammatory efficacy of AL-438 in ATDC5 cells 
ATDC5 cells were grown in 10µg/ml lipopolysaccharide (LPS) (Lot 104K4036; from 
EColi 0127:B8; Sigma) with or without Dex or AL-438 (10-6M) for 24h.  The 
medium was removed and analysed for levels of IL-1, IL-6 and TNF-α by Luminex 
technology (assay completed by Dr Alistair Gracie, Division of Immunology, 
Infection and Inflammation, University of Glasgow).  
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Fetal metatarsal organ culture 
The middle three metatarsals were aseptically dissected from 18-day-old embryonic 
Swiss mice that had been killed by decapitation.  The experimental protocol was 
approved by Roslin Institute’s Animal Users Committee and the animals were 
maintained in accordance with Home Office guidelines for the care and use of 
laboratory animals.  Bones were individually cultured at 37°C in a humidified 
atmosphere of 95% air/5% CO2 in 24-well plates (Costar) for up to 12 days.  Each 
well contained 300µl of α-MEM without nucleosides (Invitrogen) supplemented with 
0.2% BSA Cohn fraction V (Sigma), 0.1mmo/l β-glycerophosphate (Sigma), 
0.05mg/ml L-absorbic acid phosphate (Wako, Japan), 0.292mg/ml L-glutamine 
(Invitrogen), 0.05mg/ml gentamicin (Invitrogen) and 1.25µg/ml fungizone 
(Invitrogen).  Dex or AL-438 were both added at a final concentration of 10-6M in 
0.01% DMSO to the bones and the medium was changed every second or third day.  
The control groups (0.01% DMSO only) and experimental groups contained 6 
metatarsals each.  
 
Morphometric analysis 
Images were taken of the metatarsals every second or third day of culture using a 
digital camera attached to a Nikon TE300 microscope (Figure 1).  The total length of 
the bone was determined using Image Tool (Image Tool version 3.00, University of 
Texas Health Life Science Centre, San Antonio, TX).  All results are expressed as a 
percentage change from harvesting length, which was regarded as baseline to 
demonstrate the rate of growth over time.  For the determination of the size (in the 
direction of longitudinal growth) within the growth region of the distinct chondrocyte 
maturational zones, the 12-day-old metatarsals were fixed in 70% ethanol, 
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dehydrated, and embedded in paraffin wax [29].  Wax sections (10µm in thickness) 
were reacted for ALP activity for the demarcation of the hypertrophic and 
proliferating zones.  Sections were also stained with von Kossa and hematoxylin and 
eosin using standard protocols to identify the zone of cartilage mineralization [10].  
Images of the stained metatarsals were captured and the size of the ALP-negative 
proliferating zone was determined (proliferating zone = total length – (hypertrophic 
zone + mineralizing zone).  The size of the hypertrophic zone was determined by 
subtracting the von Kossa stained mineralizing zone from the ALP-positive zone, and 
the size of the mineralizing zone was determined directly from the von-Kossa stained 
sections. 
 
Cell proliferation: BrdU and PCNA staining 
BrdU (Sigma) was added (1mg/ml final concentration) to the culture medium of the 
metatarsals for the last 6h of culture on day 12.  At the end of the incubation period, 
the tissue was washed in PBS and fixed in 70% ethanol, dehydrated, and embedded in 
paraffin wax.  Sections 10µm in thickness were cut along the longitudinal axis, and 
chondrocyte nuclei with incorporated BrdU were detected using a cell proliferation kit 
(Amersham Biosciences, UK) Briefly, sections were incubated with a monoclonal 
antibody to BrdU diluted 1:50 in PBS for 1h.  After washing, the sections were 
incubated for an additional 1h in peroxidase anti-mouse IgG2a and then reacted with 
diaminobenzidine before being dehydrated and mounted in DPX.  The total number of 
BrdU positive chondrocytes within the proximal and distal growth regions was 
determined, and normalized to section area.  Sections were also stained with an 
antibody to proliferating cell nuclear antigen (PCNA) (Sigma) using a standard 
indirect immunoperoxide protocol as described for BrdU (above).     
 11 
 
Statistical Analysis 
Data were analysed by one-way analysis of variance.  All data are expressed as the 
mean ± S.E.M of at least 6 replicates within each experiment, and statistical analysis 
was performed using Minitab (Minitab 14; PA, USA).  P<0.05 was considered to be 
significant. 
 
Results 
 
Effect of AL-438 on ATDC5 cell number and proliferation  
During chondrogenesis exposure to Dex or Pred for 24h caused a concentration-
dependent reduction in [3H]-thymidine incorporation (54.5% and 29.2%, respectively, 
at 10-6M (p<0.05)), whereas exposure to AL-438 had no significant effect at any 
concentration tested (Figure 1a).  Consequently, 10-6M Dex, Pred or AL-438 was used 
for all future experiments.  Counting the cells directly in a haemocytometer chamber 
supported these results, with Dex and Pred causing a significant reduction in cell 
number at 10-6M (36.2% and 36.8% respectively (p<0.05)), and AL-438 having no 
significant effect (Figure 1b).  During the terminal differentiation phase (days 13-17), 
none of the compounds significantly altered chondrocyte proliferation or cell number 
(data not shown). 
 
Effect of AL-438 on proteoglycan production, ALP activity and expression of 
chondrocyte marker genes in ATDC5 cells 
In comparison with control cultures during the chondrogenesis period, exposure to 
Dex and Pred for 96h caused a significant reduction in proteoglycan synthesis (56% 
and 54%, respectively; p<0.05), whereas exposure to AL-438 had no effect (Figure 
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1c).  No significant differences between treatments were noted during terminal 
differentiation (data not shown).  The effect of AL-438 on terminal chondrocyte 
differentiation was assessed by ALP activity.  During chondrogenesis, ALP activity 
was significantly increased after exposure to Dex, Pred and AL-438 (p<0.05) (Figure 
1d), but no significant differences were observed during terminal differentiation (data 
not shown).  Semiquantitative PCR revealed that gene expression levels of aggrecan 
were reduced in Dex treated cells, but were unchanged in Pred or AL-438 treated cells 
(Figure 2a).  qPCR analysis confirmed a significant reduction in aggrecan expression 
with Dex (3.5-fold reduction; p<0.05), and also revealed a significant reduction in 
aggrecan with Pred (1.36-fold; p<0.05) (Figure 2b).  Caspase-3 activity was 
unchanged in Dex, Pred and AL-438 treated cells compared to controls during both 
chondrogenesis and terminal differentiation (data not shown).  TNF-α did cause a 
significant increase in Caspase-3 activity as expected. 
 
Anti-inflammatory efficacy of AL-438 in ATDC5 cells 
LPS induced IL-6 production in ATDC5 cells and this induction was reduced by the 
co-incubation Dex or AL-438 by 58.1% and 55.4%, respectively.  These results were 
significantly different (p<0.05) from IL-6 levels in LPS-only treated cells, but not 
significantly different from each other (p>0.05) (Figure 3).  Interestingly, levels of IL-
1 and TNF-α were undetected in control and test samples.  These results demonstrate 
that AL-438 has a similar anti-inflammatory efficacy to Dex in ATDC5 cells. 
 
Longitudinal bone growth and assessment of chondrocyte maturational zone sites 
Until day 7 of culture, fetal mouse metatarsals treated with Dex or AL-438 grew at a 
similar rate to controls. However, subsequently, Dex treated metatarsals were 
 13 
significantly shorter than control bones (18.5% shorter at day 10 (p<0.05) and 22.2% 
shorter at day 12 (p<0.01)), whereas AL-438 treated metatarsals continued to parallel 
control bone growth (Figure 4). The lengths of the proliferating, hypertrophic and 
mineralizing zones were measured on histological sections of 12-day-old metatarsals 
(Table 2; Figure 5).  Although, the lengths of the proliferating and hypertrophic zones 
did not significantly change between treatments, Dex significantly reduced the length 
of the mineralizing zone (57%; p<0.05).   
 
Cell proliferation in metatarsals:  BrdU and PCNA staining  
The number of proliferating chondrocytes within the metatarsals was significantly 
reduced by Dex (78.9%; p<0.05) and AL-438 (83.9%; p<0.05) (Figure 6).  
Interestingly, the majority of positive staining was observed within the cells of the 
perichondrium, with only a small number of proliferating chondrocytes being detected 
within the proliferative zone.   
 
Discussion 
 
Glucocorticoids are the most effective anti-inflammatory agents known.  However, 
the long-term use of these steroids leads to a large number of side effects, including 
growth retardation in children.  The exact mechanisms by which GC induce failure in 
the growth process are presently unclear, but early studies involving local infusion of 
GC directly into the growth plate decreased the ipsilateral tibial growth rate with no 
effects on the contralateral limb, suggesting a mechanism intrinsic to the epiphyseal 
growth plate [7].  It has also been shown that GC reduce growth plate cartilage width, 
and it has been suggested that this is due to GC inhibiting chondrocyte proliferation 
and increasing the apoptosis of terminal hypertrophic chondrocytes [8, 9].   
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The search for a novel GC that has the anti-inflammatory properties of conventional 
steroids without one or more of the side-effects has been a long-standing goal of the 
field.  Much effort has been spent on modifying the steroid backbone to achieve this, 
however, these efforts have been met with little success.  Deflazacort, a D-ring 
substituted steroid, was originally hailed as a powerful anti-inflammatory molecule 
exhibiting reduced activity in bone and glucose metabolism [29].  Initially, clinical 
data supported this notion [30, 31].  However, subsequent trials that adjusted the 
steroid dose to maintain equivalent anti-inflammatory efficacy usually needed higher 
levels of deflazacort.  Unfortunately, at these higher doses, the advantages of 
deflazacort disappeared.  The field was revived by the discovery that in order to 
repress pro-inflammatory genes, the GR binds directly to specific transcription factors 
(NFκB and AP-1) which can up- or down-regulate inflammatory genes [32, 33].  This 
represented a unique mechanism that was genetically separable from transcriptional 
activation, and initiated the search for ligands that could induce transcriptional 
repression, but reduce transcriptional activation.   
 
AL-438 is a specific, non-steroidal ligand for the GR that exhibits a unique profile 
both in vivo and in vitro.  It retains full anti-inflammatory activity but has reduced 
negative effects on osteoblasts compared to Pred  [21, 34, 35].   Interestingly, 
incubating ATDC5 cells with AL-438 had no effect on cell proliferation, cell number 
or proteoglycan synthesis, whereas, as found in previous studies, both Dex and Pred 
significantly reduced ATDC5 proliferation, cell number and proteoglycan synthesis 
[4, 36].  The lack of effect of Dex on ATDC5 apoptosis is in agreement with previous 
studies [4] but at variance with other chondrocyte studies [18] suggesting a cell type 
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dependent effect. Studies measuring the bone turnover marker osteocalcin in the 
human osteoblast cell line MG-63 have shown that AL-438 is unable to inhibit 
osteocalcin expression as efficiently as Pred [24].  In addition, AL-438 has been 
shown to exhibit a weak inhibition of osteoprotegerin in MG-63 cells compared to 
other GCs [21].  The differential effect on ATDC5 cell progression between AL-438 
and Dex and Pred may be due to the fact that AL-438 is qualitatively different in 
terms of its ability to activate or repress gene expression.  Interestingly, none of the 
compounds had an effect on ATDC5 maturation in terms of proliferation, ALP 
activity or proteoglycan production during the terminal differentiation period, a 
finding that has been reported previously [4].   
 
The mechanism of action of AL-438 is based on the hypothesis that many genes 
involved in undesirable side effects are upregulated (such as enzymes in lipid and 
muscle metabolism), whereas many pro-inflammatory genes (i.e. IL-1, IL-6 and TNF-
α) are repressed.  It has been hypothesised that upon binding to the GR, AL-438 
induces structural changes in the receptor that are different than those induced by 
other GR ligands such as Pred or Dex [21].  These structural changes promote reduced 
co-factor interactions between the GR and co-factors such as PGC-1, which is 
involved in hepatic glucose production, but do not change the interactions between 
GRIP-1 and the GR, a co-factor which plays a role in the repression of pro-
inflammatory genes [21].  This hypothesis may explain the reported maintenance of 
anti-inflammatory activity with AL-438 [21] but also its reduced effects on ATDC5 
cells as found in this study.  The proposed mechanism of action of AL-438 is also 
supported by the finding that as opposed to Dex, AL-438 does not have a detrimental 
effect on metatarsal bone growth. This finding confirms bone-sparing results from 
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previous studies on rats treated with Pred or AL-438, which used calcein and 
tetracycline labelling to show that whilst Pred significantly reduced the rate of cortical 
bone formation, AL-438 had no effect [21].  The fact that the length of the 
mineralizing zone, but not the proliferating or hypertrophic zones, was significantly 
shorter in Dex treated bones suggests that Dex is acting directly on the terminally 
differentiated chondrocytes to reduce overall bone length.  A similar finding has 
previously been found by our group [10] and others [37], and may be caused by Dex 
interfering with genes involved in the mineralization process.  The finding that Dex or 
AL-438-treated metatarsals had a similar number of proliferating chondrocytes was 
surprising when compared to the in vitro proliferation data, and could be explained by 
the suggestion that the activity of transcriptional activators such as AL-438 can vary 
under different conditions and in different tissue types [38].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
This data intriguingly suggests that bone growth within the metatarsal model is not 
wholly dependent on chondrocyte proliferation as growth retardation was not 
observed in the AL-438 treated metatarsals despite lowered proliferation.  Other 
aspects of chondrocyte dynamics such as alterations in hypertrophy may be involved 
and this requires further investigation. 
 
The finding that AL-438 maintains a similar anti-inflammatory efficacy to Dex in 
ATDC5 cells was important, as it proved that AL-438 was still fully efficacious as an 
anti-inflammatory agent in chondrocytes despite the fact that it was much less harmful 
than Dex or Pred.  The anti-inflammatory efficacy of AL-438 has previously been 
demonstrated both in vivo using the rat carrageenan-induced paw edema assay and in 
vitro in HepG2 cells and human skin fibroblasts [21].  
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To compensate for the fact that AL-438 is slightly less potent than Pred a saturating 
dose of 10-6M was used for all compounds in this study. In addition, this 
pharmacological concentration of Dex and Pred is similar to that found in chronic GC 
therapy and has been shown previously by us, and others, to inhibit both chondrocyte 
proliferation and longitudinal bone growth [4, 10].  At  10-6M the compounds fully 
occupied the receptor, therefore allowing their full efficacy as anti-inflammatory 
agents to be measured.  Although AL-438 has been shown to have similar affinity for 
the GC-receptor across a wide array of tested cell types [21, plus unpublished data] it 
also exhibits some affinity for the mineralocorticoid receptor at this concentration. 
This affinity is comparable to that of 10-6M Pred, and when tested against a variety of 
other nuclear and non-nuclear receptors, kinases and enzymes, AL-438 displayed no 
affinity up to a concentration of 10µM (unpublished).   In addition to interactions with 
its receptor, GC are also known to have non –genomic effects that are not mediated by 
the GC-receptor [39]. Although all indications are that AL-438 acts exclusively 
through the GC-receptor [21] further studies are required to establish the precise 
cellular events involved in AL-438 actions.  Nevertheless the data from this study 
suggests that AL-438 may separate anti-inflammatory activity from a number of bone 
growth-related side effects, including chondrocyte proliferation and longitudinal bone 
growth. endorses the principle for searching for novel anti-inflammatory agents with 
minimal side effects.  The reduced skeletal side effect profile of this novel selective 
glucocorticoid receptor modulator compared to other GCs could prove important in 
the search for new anti-inflammatory treatments for children. 
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Table 1 – Lengths of the proliferating, mineralizing and hypertrophic zones.   
 
Treatment Mineralizing zone (mm) 
Hypertrophic zone 
(mm) 
Proliferating zone 
(mm) 
Control 1.29 +/- 0.08 0.68 +/- 0.09 0.84 +/- 0.02 
Dexamethasone 0.74 +/- 0.19 * 0.77 +/- 0.12 0.71 +/- 0.05 a 
AL-438 1.30 +/- 0.07 0.56 +/- 0.06 0.80 +/- 0.03 
Data are expressed in mm ± sem (n = 6).  *P<0.05 compared with controls; aP = 0.06 compared with controls.
 29 
Figure 1 (A) Effect of Dex, Pred and AL-438 on cell proliferation as assessed by 
[3H]-thymidine uptake during chondrogenesis.  Effect of Dex (♦ and short dashed 
lines); effect of Pred (□ and long dashed lines); effect of AL-438 (▲ and solid line).  
Data are expressed as means ± sem (n = 6).  ***P<0.001; *P<0.05 compared with 
control treated cells.  (B) Effect of Dex, Pred and AL-438 (all 10-6M) on cell number 
during chondrogenesis.  Data are expressed as means (104) ± sem (n = 6).    (C) Effect 
of Dex, Pred and AL-438 (all 10-6M) on proteoglycan production as assessed by 
Alcian Blue staining in ATDC5 cells during chondrogenesis.  *P<0.05 compared with 
control and AL-438 treated cells.  (D)  Effect of Dex, Pred and AL-438 (all 10-6M) on 
ALP activity in ATDC5 cells during chondrogenesis.  All data are expressed as means 
± sem (n = 6).  *P<0.05 compared with control treated cells. 
 
Figure 2 (A) Semiquantitative RT-PCR analysis of the expression of Aggrecan in 
ATDC5 cells treated with Dex, Pred or AL-438 (all 10-6M).  Dex, but not Pred or AL-
438 reduces the expression of Aggrecan.  (B) Aggrecan mRNA levels as measured by 
quantitative PCR in ATDC5 cells.  All data are shown as the mean relative gene 
expression  ± sem (n=3) and normalised to GAPDH mRNA levels.  *P<0.05 
compared with control treated cells. 
 
Figure 3 -  LPS-induced IL-6 production in ATDC5 cells treated with Dex or AL-438 
(all 10-6M).  Data are expressed as means ± sem (n = 6).  *P<0.05 compared with 
control and LPS treated cells. 
 
 30 
Figure 4 -  Effect of Dex or AL-438 (10-6M) on the growth of metatarsals from 18-
day old fetal Swiss mice over a 12-day period.  Data are expressed as mean ± sem (n 
= 6).  **P<0.01 compared with controls; *P<0.05 compared with controls. 
 
Figure 5 – Digital image of d10 fetal mouse metatarsal section reacted for ALP 
activity, showing staining within both the mineralising and hypertrophic zone.  The 
location of the proliferating (PZ), mineralizing (MZ), and hypertrophic (HZ) zones 
are also illustrated.    
 
Figure 6 – Effect of Dex and AL-438 on the number of proliferating chondrocytes 
present in metatarsals (as represented by BrdU positive cells/section area).   Data are 
expressed as mean ± sem (n = 6).  ***P<0.001 compared with controls. 
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Figure 5 
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